In a recent move at Akero Therapeutics, Inc. (NASDAQ: AKRO), Chief Development Officer Yale Catriona sold shares worth more than $150,000. The transaction, which took place on September 20, 2024, ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

On April 15, Yale Catriona, the Chief Development Officer of Akero Therapeutics Inc . (NASDAQ: AKRO), engaged in a series of stock transactions involving the company’s common stock. According to the ...

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Con ...

Akero Therapeutics has been a focus of several analyst firms. Canaccord Genuity maintained a Buy rating on the company's stock, noting the potential of the drug candidate, Efruxifermin.

Here is how Akero Therapeutics, Inc. (AKRO) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Akero Therapeutics, Inc. is set to hold an investor webcast on January 27, 2025, at 8:00 a.m. ET to present preliminary topline results from its SYMMETRY study, which evaluates the efficacy of ...

Akero Therapeutics, Inc. (NASDAQ: AKRO) President and CEO Andrew Cheng recently sold shares in the company, yielding a total of $178,728. The transaction, which took place on June 11, involved the ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands ...

Stay up to date on how Akero Therapeutics Inc (0K4:XSTU) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Akero Therapeutics shares last traded at $43.15, with a volume of 76,195 shares trading hands. Specifically, Director G. Walmsley Graham bought 50,000 shares of Akero Therapeutics stock in a ...